Dana Investment Advisors Inc. Sells 3,789 Shares of IQVIA Holdings Inc. $IQV

Dana Investment Advisors Inc. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 156,268 shares of the medical research company’s stock after selling 3,789 shares during the period. IQVIA makes up about 1.0% of Dana Investment Advisors Inc.’s investment portfolio, making the stock its 14th biggest position. Dana Investment Advisors Inc. owned 0.09% of IQVIA worth $35,224,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA during the 4th quarter worth about $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA during the 4th quarter worth about $27,000. Activest Wealth Management lifted its holdings in shares of IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares during the period. Physician Wealth Advisors Inc. lifted its holdings in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. Finally, Westside Investment Management Inc. lifted its holdings in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Mizuho set a $215.00 price target on shares of IQVIA in a report on Monday, February 23rd. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Royal Bank Of Canada assumed coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Finally, Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, IQVIA currently has a consensus rating of “Buy” and an average price target of $225.69.

IQVIA Stock Down 0.7%

Shares of NYSE IQV opened at $169.56 on Friday. The stock has a market cap of $28.30 billion, a P/E ratio of 21.01, a P/E/G ratio of 1.63 and a beta of 1.18. The firm has a 50 day moving average price of $170.14 and a 200 day moving average price of $199.19. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.